Trifluridine/Tipiracil (TAS-102)

TAGS



Trifluridine/Tipiracil (TAS-102) TAGS	Trifluridine/Tip
PRELIMINARY SCORE	
CURATIVE	CURATIVE
	Overall Surviva
NON-CURATIVE	NON-CURAT
Os	NON-CURAT
ADJUSTMENTS	Overall Surviva
Quality of life	
	Progression-Fre
No QoL benefit	
	Non-inferiority (
Serious and disabling adverse effects	
	Overall Respon
	Overall Surviva
Other adjustments	INFORMATIO
	Tumour type: Therapeutic Ir
	gastroesopha prior systemic
	Experimental
	Control Arm: F

		SCORE	
CURATIVE			
Overall Surviva	ıl / Disease-Free Surviva	ıl / Pathological Comp	elete Response
NON-CURAT	IVE		
	•	3	
Overall Surviva	ıl		
Progression-Fr	ee Survival		
Non-inferiority	(Improved Quality of Life	or Reduced Adverse	Events) / Response Rate
Overall Respor	nse Rate / Duration of Re	esponse	
Overall Surviva	ıl / Disease-Free Surviva	ıl / Pathological Comp	olete Response
INFORMATIO	ON		
Therapeutic I gastroesopha prior systemic	geal junction, in patie c treatment regimens f Arm: Trifluridine/Tipira	pastric cancer includ nts who have been for advanced diseas	ding adenocarcinoma of the previously treated with ≥2 se

